Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 12091424 Rapamycin derivatives

Patent 12091424 was granted and assigned to Novartis on September, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Novartis

Current Assignee

Novartis

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

120914240

Patent Inventor Names

Tea Shavlakadze0

Silvio Roggo0

David Jonathan Glass0

Andrew William Patterson0

Michael Connolly0

Manuel Mihalic0

Simone Bonazzi0

Date of Patent

September 17, 2024

Patent Application Number

174994330

Date Filed

October 12, 2021

Patent Citations

‌

US Patent 9669032 Enhanced treatment regimens using mTOR inhibitors

‌

US Patent 8906374 Combination therapy with CD4 lymphocyte depletion and mTOR inhibitors

‌

US Patent 9358236 Combinations of therapeutic agents for use in the treatment of neurodegenerative diseases

‌

US Patent 9427463 Combination therapy with CD4 lymphocyte depletion and mTOR inhibitors

‌

US Patent 9683048 Antibody molecules to PD-1 and uses thereof

Patent Primary Examiner

‌

Po-Chih Chen

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 12091424 Rapamycin derivatives

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API